Zhongchao Inc. Prices $5 Million Public Offering

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: 6 days ago

0mins

ZCMD-33.33%Explore Agentic TradingLet AI Trade for You

Source: PRnewswire

Zhongchao Inc. (ZCMD) has seen a significant decline of 12.59% in pre-market trading, hitting a 52-week low.

The company announced a public offering priced at $0.54 per unit, expecting gross proceeds of approximately $5 million. This offering consists of 9,259,260 units, each comprising one Class A ordinary share and one warrant, with an initial exercise price of $0.594 per share. The offering reflects the company's ability to raise capital and indicates strong market interest in Zhongchao's future growth. Univest Securities, LLC acts as the sole placement agent for the offering, showcasing its expertise in facilitating this financing.

The market's reaction to the offering has been cautious, as evidenced by the stock's significant drop in pre-market trading. Investors may be reassessing their strategies in light of the company's current valuation and future prospects.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy ZCMD?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on ZCMD

About ZCMD

Zhongchao Inc is a holding company engaged in the provision of healthcare information, education, and training services to healthcare professionals and the public in China. The Company operates its businesses through two segments. MDMOOC Services segment engages in the provision of training and education services and assistance in patient-aid projects. Sales of Patented Drugs segment mainly engages in the sales of patented drugs. Under the MDMOOC brand, the Company offers a wide range of online and onsite health information services, healthcare education programs, and healthcare training products, consisting primarily of clinical practice training, open classes of medical topics, interactive case studies, academic conference and workshops, continuing education courses, and articles and short videos with educational healthcare content to healthcare professionals as well as the public.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Zhongchao Inc. Announces Share Consolidation Plan

4 hours agoPRnewswire

Share Consolidation Details: Zhongchao Inc. will implement a 1-for-31 share consolidation on June 8, 2026, where every 31 Class A ordinary shares will convert into one share, aimed at maintaining its Nasdaq listing and enhancing market confidence.
Capital Structure Changes: Prior to the consolidation, the company has 79,685,696 Class A and 624,972 Class B ordinary shares, with an expected post-consolidation total of approximately 2,570,507 Class A and 20,161 Class B shares, indicating efforts to optimize capital structure.
Shareholder Impact: The consolidation will uniformly affect all shareholders, with adjustments for fractional shares, but will not alter any shareholder's percentage interest in the company's total shares, ensuring stability in shareholder equity.
Management Approval: The consolidation plan was approved by shareholders on February 10, 2026, and by the board of directors on March 31, 2026, reflecting transparency in corporate governance and compliance in decision-making.

Zhongchao Announces 1-for-31 Share Consolidation

3 hours agoseekingalpha

Share Consolidation Plan: Zhongchao has announced a 1-for-31 share consolidation of its ordinary shares, aiming to enhance the stock price per share by consolidating shares with a par value of $0.008 to meet Nasdaq Capital Market listing requirements.
Trading Schedule: The consolidated ordinary shares will begin trading on Nasdaq under the same ticker symbol “ZCMD” starting June 8, ensuring that investors can smoothly transition to trading post-consolidation.
Listing Maintenance Objective: The primary goal of this share consolidation is to maintain the company's listing on Nasdaq, reflecting its commitment to compliance and market recognition.
Market Reaction Expectations: While the consolidation may have a positive short-term impact on the stock price, the company must continuously monitor market assessments of its long-term growth potential to ensure shareholder confidence and investor support.

Zhongchao Inc. Prices Public Offering at $0.54 per Unit

3 days agoNASDAQ.COM

Offering Size: Zhongchao Inc. (ZCMD) has priced its best-efforts public offering at $0.54 per unit for a total of 9.26 million units, expecting gross proceeds of approximately $5 million, which highlights the company's ability to raise capital in the market.
Subscription Details: Each unit consists of one Class A ordinary share and a warrant with an exercise price of $0.594 per share, expiring six months post-issuance, indicating the company's appeal to investors and potential returns.
Market Performance: ZCMD's stock has traded between $0.08 and $12.18 over the past year, currently at $0.09, down 42.28% from Friday's close of $0.17, reflecting market caution regarding its future performance.
Underwriter Role: Univest Securities, LLC serves as the sole placement agent for this offering, underscoring its significance and expertise in facilitating the company's capital-raising efforts.

Biotech Stocks Show Significant Pre-Market Activity

3 days agoNASDAQ.COM

Significant Pre-Market Gains: Genenta Science S.p.A. (GNTA) surged 135% to $2.42 in pre-market trading, indicating strong market optimism about its potential breakthroughs, which may attract more investor interest.
Healthy Choice Performance: Healthy Choice Wellness Corp. (HCWC) rose 30% to $0.43, reflecting increased market demand for its products, potentially boosting future sales and market share for the company.
Pre-Market Decliners: Zhongchao Inc. (ZCMD) fell 34% to $0.11 in pre-market trading, signaling market concerns about its outlook, which may lead investors to reassess their investment strategies.
Overall Market Sentiment: The overall pre-market activity in the biotech sector shows significant volatility, as investors seek potential breakout opportunities, which could influence trading strategies in the market.